



(51) International Patent Classification:

A61K 38/17 (2006.01) C12N 15/85 (2006.01)
C07K 14/00 (2006.01) C12N 7/00 (2006.01)
C07K 19/00 (2006.01) A61K 38/00 (2006.01)

(21) International Application Number:

PCT/US2020/012589

(22) International Filing Date:

07 January 2020 (07.01.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/789,344 07 January 2019 (07.01.2019) US
62/876,346 19 July 2019 (19.07.2019) US
62/941,176 27 November 2019 (27.11.2019) US

(71) Applicant: **SHATTUCK LABS. INC.** [US/US]; 1018
West 11th Street, Austin, TX 78703 (US).

(72) Inventors: **SCHREIBER, Taylor**; c/o Shattuck Labs, Inc.,
1018 West 11th Street, Austin, TX 78703 (US). **FROMM,
George**; c/o Shattuck Labs, Inc., 1018 West 11th Street,
Austin, TX 78703 (US). **DE SILVA, Suresh**; c/o Shattuck
Labs, Inc., 1018 West 11th Street, Austin, TX 78703 (US).


(74) Agent: **ALTIERI, Stephen, L.** et al.; Morgan, Lewis &
Bockius LLP, 1111 Pennsylvania Avenue, NW, Washing-
ton, DC 20004 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


(54) Title: HETERODIMERIC PROTEINS FOR MODULATING GAMMA DELTA T CELLS

FIG. 1



Other Human Butyrophilin Targets: BTNL1, BTNL2, BTNL3, BTNL4, BTNL5, BTNL6, BTNL7, BTNL8, BTNL9, BTNL10, SKINT

Potential Cancer Antigens Targeted with scFv Scaffolds: CD2, PSMA, B2M, CD133, B2M, CD20, CD33, CD38, CEA, CLEC13A, DLL3, EGFRvIII, EpCAM, CD307, FLT3, GPC3, gpA33, GPCR50, HER2, MUC16, P-cadherin, SSTR2, neurofilin, etc.



(57) Abstract: The present technology relates, inter alia, to compositions and methods, including heterodimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity.

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))